

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number  
**WO 03/057898 A3**

(51) International Patent Classification<sup>7</sup>: **C07H 21/04,**  
A61K 31/70, C12N 15/00

**HART, Lucy, Vulchanova** [BG/US]; 2117 Niles Avenue,  
St. Paul, MN 55116 (US).

(21) International Application Number: PCT/US02/41833

(74) Agent: **ELLINGER, Mark, S.**; Fish & Richardson P.C.,  
P.A., Suite 3300, 60 South Sixth Street, Minneapolis, MN  
55402 (US).

(22) International Filing Date:

31 December 2002 (31.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/346,155 31 December 2001 (31.12.2001) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 60/346,155 (CON)  
Filed on 31 December 2001 (31.12.2001)

(71) Applicant (for all designated States except US): **ALGOS  
THERAPEUTICS, INC.** [US/US]; 4335 Rosewood Lane  
North, Plymouth, Minnesota 55442 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHUSTER, Samuel,**  
J. [US/US]; 6712 Apache Road, Edina, MN 55439 (US).  
**ARVIDSSON, Ulf, N., G.** [SE/SE]; Gardstigen 4, Lidingsö  
(SE). **STONE, Laura, S.** [CA/US]; 2242 Nevada Avenue  
South, Apt. 19, St. Louis Park, MN 55426 (US). **ZHANG,**  
**Hong-Yan** [CN/SE]; Sevensvagen 4, Sundbyberg (SE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CIL, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
23 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND MATERIALS FOR MODULATING P2X2

(57) Abstract: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of P2X2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding P2X2.

WO 03/057898 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/41833

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; A61K 31/70; C12N 15/00

US CL : 536/23.1, 24.5; 514/44; 435/320.1, 325, 375

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 24.5; 514/44; 435/320.1, 325, 375

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6,242,216 B1 (LYNCH et al) 05 June 2001 (05.06.2001), see column 16-17, Example 2, Figure 6A-6B.	1
---		-----
Y		5-8
A	MA et al. Synthetic oligonucleotides as therapeutics: the coming of age. Biotechnology Annual Review. July 2000, Vol. 5, pages 155-196, especially pages 167-168.	1, 5-8

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

20 June 2003 (20.06.2003)

Date of mailing of the international search report

16 JUL 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized Officer  
Janet L. Epps-Ford, PhD.

Telephone No. 703-308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/41833

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 2-4  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Applicant's have not complied with the sequence rules since the CRF that was submitted is not technically sound. Additionally, the Application does not have a paper copy of the Sequence Listing.
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

PCT/US02/41833

**Continuation of B. FIELDS SEARCHED Item 3:**  
CAplus, Registry, USPAT, EPO, JPO, Medline, Biosis  
search terms: P2X2, antisense, aptamer, triplex, ribozyme